1. Home
  2. KLAC vs AZN Comparison

KLAC vs AZN Comparison

Compare KLAC & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KLA Corporation

KLAC

KLA Corporation

N/A

Current Price

$195.36

Market Cap

270.0B

Sector

Technology

ML Signal

N/A

Logo AstraZeneca PLC

AZN

AstraZeneca PLC

N/A

Current Price

$159.46

Market Cap

250.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KLAC
AZN
Founded
1975
1992
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
270.0B
250.7B
IPO Year
1994
1995

Fundamental Metrics

Financial Performance
Metric
KLAC
AZN
Price
$195.36
$159.46
Analyst Decision
Buy
Buy
Analyst Count
30
12
Target Price
★ $232.77
$206.91
AVG Volume (30 Days)
★ 6.9M
2.4M
Earning Date
10-28-2026
10-30-2026
Dividend Yield
0.47%
★ 2.03%
EPS Growth
N/A
★ N/A
EPS
★ 3.66
N/A
Revenue
N/A
N/A
Revenue This Year
$33.52
$7.52
Revenue Next Year
$18.50
$6.16
P/E Ratio
$53.55
★ $31.91
Revenue Growth
N/A
N/A
52 Week Low
$165.93
$80.48
52 Week High
$2,431.29
$212.71

Technical Indicators

Market Signals
Indicator
KLAC
AZN
Relative Strength Index (RSI) 51.65 44.42
Support Level $167.59 $154.89
Resistance Level $214.80 $169.77
Average True Range (ATR) 6.79 2.79
MACD 3.01 -0.43
Stochastic Oscillator 60.41 31.09

Price Performance

Historical Comparison
KLAC
AZN

About KLAC KLA Corporation

KLA is one of the largest semiconductor wafer fabrication equipment, or WFE, manufacturers in the world. It specializes in the market segment of semiconductor process control, wherein machines inspect semiconductor wafers during research and development and manufacturing for defects and verify precise measurements. In this section of the market, KLA holds a majority share. It also has a small exposure to the etch and deposition segments of the WFE market. It counts as top customers the largest chipmakers in the world, including TSMC and Samsung.

About AZN AstraZeneca PLC

A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Share on Social Networks: